Cipla cuts prices of 3 cancer drugs by around 64%

Drugmaker Cipla cut prices of three cancer drugs between 50% and 64% with immediate effect, after it announced similar price cuts for three drugs early this year.

Lung cancer drug Erlocip would cost Rs 9,900 for 30 tablets instead of Rs 27,000 earlier, while breast cancer treatment Docetax would be priced Rs 1,650 instead of Rs 3,300, Cipla said in a statement on Thursday.

Cipla last month won a case against Roche Holding, which accused the Indian company of infringing patent on cancer drug Tarceva, which Cipla sells under the brand name Erlocip.

Capegard, another drug to treat metastatic colorectal and colon caner, would be priced Rs 600 for 10 tablets instead of Rs 1,200 rupees, it said.